SOTIO Announces Clinical Collaboration with MSD to Evaluate IL-15 Superagonist, SOT101, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors

Pat Purcell
Meeting Engagement

Bud Bilanich
Success Coach

Joey Cohen
Medication Adherence

Liz Kane
Impactful Strategy

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice

Amy Giles
Increasing Engagement

Suma Ramadas, PhD
Medical Affairs

Matt Turner
Patient Affordability

Matthew Durham
Omnidynamic Marketing

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access